Phosphodiesterase Inhibitor Improves Renal Tubulointerstitial Hypoxia of the Diabetic Rat Kidney

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2012 Jun 19

PMID 22707888

Citations 17

Authors

Hui-Kyoung Sun

Yun Mi Lee

Kum Hyun Han

Han-Seong Kim

Seon-Ho Ahn

Sang-Youb Han

Affiliations

Soon will be listed here.

Abstract

Background/aims: Renal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a nonselective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney.

Methods: PTX (40 mg/kg, p.o.) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue hypoxia, we examined hypoxic inducible factor-1α (HIF-1α), heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1α in renal tubule cells.

Results: PTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1α, VEGF, and GLUT-1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX significantly decreased mRNA expression of HIF-1α and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. The expression of HIF-1α protein was significantly increased at 4 and 8 weeks in tubules in the diabetic rat kidney. PTX tended to decrease HIF-1α protein expression at 8 weeks. To examine whether PTX had a direct effect on renal tubules, normal rat kidney cells were stimulated with CoCl(2) (100 µM), which enhanced HIF-1α mRNA and protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) treatment. PTX had no effect on HIF-1α expression.

Conclusions: PTX attenuates tubular hypoxia in the diabetic kidney.

Citing Articles

Astragaloside IV attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation.

Li X, Dong X, Zhang L, Zhang S, Huang W, Wang C Front Pharmacol. 2024; 15:1285797.

PMID: 38572426 PMC: 10987761. DOI: 10.3389/fphar.2024.1285797.

Chronic sildenafil citrate use decreases retinal vascular endothelial growth factor expression in diabetic rats: a pilot study.

Sorour O, Nassar E, Sarhan N, El-Anwar N, Elkholy R, Tahoon D Int J Retina Vitreous. 2023; 9(1):42.

PMID: 37460929 PMC: 10351124. DOI: 10.1186/s40942-023-00480-x.

The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease.

Liu H, Li Y, Xiong J Molecules. 2022; 27(21).

PMID: 36364144 PMC: 9657345. DOI: 10.3390/molecules27217318.

Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?.

Leehey D Kidney360. 2022; 1(4):292-299.

PMID: 35372914 PMC: 8809273. DOI: 10.34067/KID.0001252019.

Ferroptosis Enhanced Diabetic Renal Tubular Injury HIF-1α/HO-1 Pathway in db/db Mice.

Feng X, Wang S, Sun Z, Dong H, Yu H, Huang M Front Endocrinol (Lausanne). 2021; 12:626390.

PMID: 33679620 PMC: 7930496. DOI: 10.3389/fendo.2021.626390.

References

McCormick B, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G . The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008; 52(3):454-63. DOI: 10.1053/j.ajkd.2008.01.025. View

Boolell M, Allen M, Ballard S, Gepi-Attee S, Muirhead G, Naylor A . Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996; 8(2):47-52. View

Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R . Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res. 1997; 29(10):491-5. DOI: 10.1055/s-2007-979086. View

Sanz M, Alvarez A, Piqueras L, Cerda M, Issekutz A, Lobb R . Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol. 2002; 135(8):1872-81. PMC: 1573309. DOI: 10.1038/sj.bjp.0704644. View

Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T . Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia. 2001; 44(8):1034-42. DOI: 10.1007/s001250100593. View

Ohtomo S, Nangaku M, Izuhara Y, Takizawa S, van Ypersele de Strihou C, Miyata T . Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant. 2007; 23(4):1166-72. DOI: 10.1093/ndt/gfm715. View

Teixeira M, Gristwood R, Cooper N, Hellewell P . Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. Trends Pharmacol Sci. 1997; 18(5):164-71. DOI: 10.1016/s0165-6147(97)01049-3. View

Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K . Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005; 16(12):3631-41. DOI: 10.1681/ASN.2005050522. View

Cheung P, Yang G, Boden G . Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism. 2003; 52(11):1496-500. DOI: 10.1016/s0026-0495(03)00271-3. View

10.

Catrina S, Okamoto K, Pereira T, Brismar K, Poellinger L . Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes. 2004; 53(12):3226-32. DOI: 10.2337/diabetes.53.12.3226. View

11.

Fine L, Bandyopadhay D, Norman J . Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000; 75:S22-6. View

12.

Frampton J, Brogden R . Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging. 1995; 7(6):480-503. DOI: 10.2165/00002512-199507060-00007. View

13.

Katavetin P, Miyata T, Inagi R, Tanaka T, Sassa R, Ingelfinger J . High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol. 2006; 17(5):1405-13. DOI: 10.1681/ASN.2005090918. View

14.

Ries M, Basseau F, Tyndal B, Jones R, Deminiere C, Catargi B . Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging. 2002; 17(1):104-13. DOI: 10.1002/jmri.10224. View

15.

Baines A, Ho P . Glucose stimulates O2 consumption, NOS, and Na/H exchange in diabetic rat proximal tubules. Am J Physiol Renal Physiol. 2002; 283(2):F286-93. DOI: 10.1152/ajprenal.00330.2001. View

16.

Tanahashi M, Hara S, Yoshida M, Hisa H, Satoh S . Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs. J Pharmacol Exp Ther. 1999; 289(3):1533-8. View

17.

Chang S, Cha B, Yoo S, Ahn Y, Song K, Han J . The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. Korean J Intern Med. 2001; 16(2):87-92. PMC: 4531709. DOI: 10.3904/kjim.2001.16.2.87. View

18.

Goy M . cGMP: the wayward child of the cyclic nucleotide family. Trends Neurosci. 1991; 14(7):293-9. DOI: 10.1016/0166-2236(91)90140-p. View

19.

Palm F, Cederberg J, Hansell P, Liss P, Carlsson P . Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia. 2003; 46(8):1153-60. DOI: 10.1007/s00125-003-1155-z. View

20.

Lee S, Han S, Li J, Lee S, Jung D, Kwak S . Induction of heme oxygenase-1 protects against podocyte apoptosis under diabetic conditions. Kidney Int. 2009; 76(8):838-48. DOI: 10.1038/ki.2009.286. View